Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Repligen (RGEN) stock in plain English

Free brief · no signupStart here
RGENPublished Nov 16, 2026
Repligen Corp
Healthcare · Medical Instruments & Supplies
Manufactures bioprocessing equipment and consumables used by pharmaceutical companies to purify biologic drugs.
Assets:
Global Production NetworkOperates primary manufacturing facilities across Massachusetts, California, Sweden, and Germany.
OPUS ColumnsDelivers pre-packed chromatography columns used to separate target proteins during manufacturing.
Filtration PortfolioProduces hollow fiber modules and flat-sheet cassettes for fluid separation and concentration.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

63
OPS ScoreOperating finances
Latest quote
-1.38%$170.29
$10.89B
n/a (loss)
$805.74M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 16, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was RGEN. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Repligen (RGEN) do?

Repligen Corp (RGEN) is a U.S.-listed company in Healthcare (Medical Instruments & Supplies). What it does: Manufactures bioprocessing equipment and consumables used by pharmaceutical companies to purify biologic drugs. Produces consumable filtration tools, pre-packed columns, and analytical instruments used in biologic drug. It is worth $10.89B on the market and sold $805.74M over the last year.

Market cap
$10.89B
P/E ratio
None (reported a loss)
Annual sales
$805.74M
Sector
Healthcare
Industry
Medical Instruments & Supplies
Brief updated
Nov 16, 2026

Brands and businesses behind RGEN

  • OPUS: Sells pre-packed chromatography columns to biologic drug developers for protein purification processes.
  • KrosFlo: Produces hollow fiber filtration systems and single-use flow paths for downstream fluid management.
  • CTech: Manufactures optical spectroscopy tools that measure protein concentrations during biologic drug development.
  • TangenX: Sells flat-sheet tangential flow filtration cassettes used for concentrating and descaling biologic solutions.
  • ARTeSYN: Supplies automated single-use fluid management valves and flow components for biopharma manufacturing.

RGEN’s flags, in plain English

Each flag is a number from Repligen’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.

Stupid Cash

Can pay this year's bills 9.9 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Still Climbing

Sales up 15.1% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Low debt

Low debt, only 33% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Burning Cash

Losing money, profit margin of -1.5%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about RGEN

How big is Repligen?

Repligen’s market cap is $10.89B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $805.74M: what customers paid the company over the last year, before any costs.

What is RGEN’s P/E ratio?

RGEN has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with RGEN?

Revenue depends heavily on capital spending budgets and inventory management decisions across biopharmaceutical drug developers. That is one risk on Repligen’s card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Repligen’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. RGEN’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card